 |
 |
|---|
PRELIMINARY SCIENTIFIC PROGRAMME
• Symposia |
Friday, June 22 2007 – 8.00-8.45 |
Deciphering the role of C-reactive protein in human diseases |
Mark Pepys, London, United Kingdom |
Saturday, June 23 2007 – 8.00-8.45 |
Chronic Kidney Disease: a new public health problem Chronic Kidney Disease: a new public health problem |
Andrew S. Levey, Boston, U.S.A. |
Sunday, June 24 2007 – 8.00-8.45 |
Renal phosphate handling: from cell physiology to modern integrative renal physiology |
Heini Murer, Zurich, Switzerland |
Friday, June 22 2007 – 9.00-10.30 |
Genetics and development |
- Orchestrating kidney development |
Adrian Woolf, London, United Kingdom |
- 5 free communications |
Friday, June 22 2007 – 9.00-10.30 |
Mechanisms of progression and CVD-CKD interaction |
- Intrarenal inflammation and oxidative stress as a common final pathway in salt-sensitive hypertension |
Bernardo Rodriguez Iturbe, Maracaibo, Venezuela |
- 5 free communications
|
Friday, June 22 2007 – 10.30-12.00 |
Chronic kidney disease 1 |
Causes and consequences of sympathetic hyperactivity in chronic kidney disease |
Peter Blankestijn, Utrecht, the Netherlands |
- 5 free communications
|
Friday, June 22 2007 – 10.30-12.00 |
Potential interventions and therapies |
- Premature vascular senescence in renal disease: Methuselah’s dilemma |
Michael Goligorsky, New York, U.S.A. |
- 5 free communications
|
Friday, June 22 2007 – 14.00-15.30 |
Transplantation
|
- An old for old strategy in renal transplantation |
Ulrich Frei, Berlin, Germany |
- 5 free communications
|
Friday, June 22 2007 – 14.00-15.30 |
Novel markers for CKD and glomerular disease |
- Familial aggregation of primary glomerular diseases: genetics at population level |
Francesco Scolari, Brescia, Italy |
- 5 free communications
|
Friday, June 22 2007 – 15.45-17.15 |
Lupus, fibrosis, renal failure |
- PI3 kinase inhibitors as therapeutic agents in experimental lupus nephritis |
Ana Clara Carrera, Madrid, Spain |
- 5 free communications
|
Saturday, June 23 2007 – 9.00-10.30 |
Immunity and inflammation |
- 6 free communications
|
Saturday, June 23 2007 – 9.00-10.30 |
Novel therapies and insights in dialysis and transplantation |
- Update on the role of humoral rejection on long-term transplant kidney survival |
Heinz Regele, Vienna, Austria |
- 5 free communications
|
Saturday, June 23 2007 – 10.30-12.00 |
Bone disease |
- 6 free communications
|
Saturday, June 23 2007 – 14.00-15.30 |
Tomorrow’s tools today? |
- Urinary proteomics: a bright future? |
Joost Schanstra, Toulouse, France |
- 5 free communications |
Saturday, June 23 2007 – 14.00-15.30 |
Scientific techniques for probing renal disease |
- MaxiP potassium channel and altered vasoregulation in hypoxia |
Javier Navarro Antolin, Seville, Spain |
- 5 free communications |
Saturday, June 23 2007 – 15.45-17.15 |
Cardiovascular complications |
- 6 free communications |
Saturday, June 23 2007 – 15.45-17.15 |
Genes, molecules and markers in chronic kidney disease |
- Cellular and molecular aspects of IgA nephropathy |
Cees Van Kooten, Leiden, the Netherlands |
- 5 free communications |
Saturday, June 23 2007 – 15.45-17.15 |
Clinical Epidemiology |
- 6 free communications |
Saturday, June 23 2007 – 15.45-17.15 |
Endothelium, cardiovascular and renal effects |
- Building on Greek heritage: Mediterranean diet for a healthy long life |
Antonia Trichopoulou, Athens, Greece |
- 5 free communications |
Sunday, June 24 2007 – 9.00-10.30 |
Anaemia |
- 6 free communications |
Sunday, June 24 2007 – 9.00-10.30 |
Basic Science in hypertension or diabetes |
- 6 free communications
|
Sunday, June 24 2007 – 9.00-10.30 |
Dialysis and transplant – mortality and outcomes |
- Bench to bedside educated investigators in Europe |
Marc E De Broe, Antwerp, Belgium |
- 5 free communications
|
Sunday, June 24 2007 – 11.00-12.30 |
Chronic kidney disease 2 |
- Membranous nephropathy. Old therapies or new treatments |
Claudio Ponticelli, Milan, Italy |
- 5 free communications
|
Sunday, June 24 2007 – 11.00-12.30 |
Dialysis access – fistulae, lines and outcomes |
- Surrogate markers in clinical studies in nephrology |
Marcello Tonelli, Edmonton, Canada |
- 5 free communications
|
Friday, June 22 2007 – 9.00-10.30 |
Haemodialysis adequacy: indicators and clinical practice |
- Dialysis adequacy in 2007: do we need new indicators based on middle molecules removal? |
Raymond Vanholder, Ghent, Belgium |
- Should we incorporate biomarkers of LV mass and function and extracellular fluid volume in the clinical management of ESRD patients?
|
Carmine Zoccali, Reggio Calabria, Italy
|
- Are inflammation markers useful indicators for monitoring haemodialysis adequacy?
|
Christoph Wanner, Würzburg, Germany
|
Friday, June 22 2007 – 9.00-10.30 |
Diabetic Nephropathy: environmental and genetic threats
|
- Environmental risk factors and mechanisms of renal damage in diabetic nephropathy: from the bench to the clinic
|
Jesus Egido, Madrid, Spain
|
- MODYs: genetic epidemiology of the expanding spectrum of renal involvement |
Dominique Chauveau, Toulouse, France
|
- Towards identification of genes involved in renal disease progression
|
Fabiola Terzi, Paris, France
|
Friday, June 22 2007 – 9.00-10.30 |
Perspectives in renal disease progression
|
- Blood pressure lowering vs selection of antihypertensive agents in CKD: still a dilemma
|
Luis Ruilope, Madrid, Spain
|
- The endothelium as a treatment target in CKD
|
Danilo Fliser, Hannover, Germany |
- Optimising renoprotective strategies: new perspectives
|
Dick De Zeeuw, Groningen, the Netherlands
|
- ACE inhibitors and Angiotensin II antagonists and renal disease progression: from clinical trials to sound meta-analysis
|
Francesco Locatelli, Lecco, Italy
|
Friday, June 22 2007 – 9.00-10.30 |
Regenerative Nephrology
|
- Treatment of acute renal failure by administration of bone marrow-derived mesenchymal stromal cells
|
Claudia Lange, Hamburg, Germany |
- Turnover and replacement of endothelial cells as major mechanism in the maintenance of vascular integrity within the kidney. Implications for renal disease and allograft rejection |
Ton Rabelink, Leiden, the Netherlands |
- Mechanism(s) of renal fibrosis: can it be reverted?
|
Christos Chatziantoniou, Paris, France |
Friday, June 22 2007 – 10.30-12.00 |
- NephroQUEST Update |
Carmine Zoccali, Reggio Calabria, Italy |
Kitty Jager, Amsterdam, the Netherlands |
- Has the rise in the incidence of Renal Replacement Therapy in developed countries come to an end? |
Kitty Jager, Amsterdam, the Netherlands |
- Past, present and future of young adults on Renal Replacement Therapy: implications of the timing of transplantation |
Vianda Stel, Amsterdam, the Netherlands |
- Implementation of EBP Guidelines concerning haemodialysis dose quantification: how far are we? |
Cécile Couchoud, Saint Denis La Plaine, France |
- How can we improve our ERA-EDTA coding systems and definitions to increase comparability between renal registry data? |
Keith Simpson, Glasgow, United Kingdom |
Friday, June 22 2007 – 14.00-17.00 |
Chair: Rosanna Coppo, Turin, Italy and Paul Kimmel, Washington, U.S.A. |
- Parenchymal Renal Disease |
Richard Glassock, Los Angeles, U.S.A |
- Transplantation |
Anil Chandraker, Boston, U.S.A |
- Bone and Mineral Metabolism |
David Bushinsky, Rochester, U.S.A |
- Clinical Nephrology |
Biff Palmer, Dallas, U.S.A |
Friday, June 22 2007 – 14.00-15.30 |
Renovascular Forum: imaging, screening and the perils for the heart in renal ischemia |
- Renovascular disease imaging. The potential of new non-invasive methods: MR perfusion imaging
|
Philip Kalra, Salford, United Kingdom
|
- Renovascular disease screening in high-risk populations: interactions of cardiologist and nephrologist
|
Johannes Mann, Munich, Germany |
- Getting to the “heart of the matter” - Combatting high cardiovascular risk in renovascular disease
|
David Goldsmith, London, United Kingdom |
Friday, June 22 2007 – 14.00-15.30 |
Countering the Chronic Kidney Disease epidemics
|
- Chronic kidney disease as a world scale public health challenge |
Meguid El Nahas, Sheffield, United Kingdom
|
- National Societies: how to deal for controlling the burden of CKD
|
Angel De Francisco, Santander, Spain
|
- What is of more benefit to prevent ESRD: screening for eGFR or screening for albuminuria? |
Ron Gansevoort, Groningen, the Netherlands
|
- Get Nephrology out of the hospital: the renal clinic of the third millennium
|
Adeera Levin, Vancouver, Canada
|
Friday, June 22 2007 – 14.00-15.30 |
Endocrine/paracrine functions of the kidney
|
- Rapid non-genomic mechanisms of aldosterone
|
Ole Skott, Odense, Denmark |
- Novel mechanisms regulating renin gene expression
|
Armin Kurtz, Regensburg, Germany
|
- The role of HIF in protection against ischemic renal injury
|
Kai-Uwe Eckardt, Erlangen, Germany |
Friday, June 22 2007 – 15.45-17.15 |
Hypertension genes, renal and cardiovascular phenotypes and the unabating environmental challenge of salt
|
- Salt intake, hypertension and cardiovascular diseases. Will the dilemma be ever solved?
|
Eberhard Ritz, Heidelberg, Germany |
- Sodium storage and BP control: a novel component controlling the salt-BP relationship |
Jens Titze, Erlangen, Germany
|
- Salt sensitivity as a predisposing factor for nephrosclerosis and diabetic nephropathy
Paolo Ferrari, Fremantle-Perth, Australia |
- The structural cardiac effects of salt loading: beyond blood pressure elevation |
Javier Diez, Pamplona, Spain |
Friday, June 22 2007 – 15.45-17.15 |
New pathways to renal damage |
- Innate immunity stimuli, toll like receptors and renal glomerulonephritis
|
Hans-Joachim Anders, Munich, Germany
|
- Transcriptional control mechanism in human glomerular diseases
|
Matthias Kretzler, Ann Arbor, U.S.A.
|
- Investigating alloimmunization in glomerular diseases
|
Pierre Ronco, Paris, France |
- Countering ADMA as a new pathway for retarding renal disease progression |
Seiji Ueda, Kurume, Japan
|
Friday, June 22 2007 – 15.45-17.15 |
Immuno-mediated renal diseases: treatment options of the near future
|
- PDGF antagonism in progressive mesangioproliferative glomerulonephritis |
Tammo Ostendorf, Aachen, Germany |
- Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney
|
Hans-Peter Marti, Bern, Switzerland |
- Antibody blockade of TNF-alpha in experimental crescentic glomerulonephritis |
Charles Pusey, London, United Kingdom |
- NF-kB as a target to treat glomerulonephritis |
Alessandro Amore, Turin, Italy |
Friday, June 22 2007 – 15.45-17.15 |
IgA nephropathy, innate immunity and infections
|
- Innate immunity in IgA nephropathy
|
Rosanna Coppo,Turin, Italy
|
- Genetic susceptibility to IgAN and genetic risk factors for progression in IgAN
|
Francesco Paolo Schena, Bari, Italy
|
- Complement in innate immunity and in IgAN |
Mohamed R. Daha, Leiden, the Netherlands |
- Is tonsillectomy an effective therapeutic option in IgAN?
|
John Feehally, Leicester, United Kingdom |
Saturday, June 23 2007 – 9.00-10.30 |
Myeloma and light chain disease: a continuous clinical challenge |
- Removal of nephrotoxic free light chains by haemodialysis |
Arthur R. Bradwell, Birmingham, United Kingdom
- Myeloma kidney: towards novel therapies. New insights from in vitro and in vivo models of renal injury |
Vecihi Batuman, New Orleans, U.S.A. |
- AL-Amyloidosis and other light chain deposition diseases: novel treatment perspectives
|
Arnaud Jaccard, Limoges, France
|
Saturday, June 23 2007 – 9.00-10.30 |
The cardiovascular pandemic of ESRD: new insights on the hidden fire |
- Adipokines in end-stage renal disease - fat tissue send nephrologists a message |
Peter Stenvinkel, Stockholm, Sweden |
- Triiodothyronine in ESRD: a key player in inflammation and malnutrition or an innocent bystander?
|
Francesca Mallamaci, Reggio Calabria, Italy |
- Exploring the complexity of inflammation and cardiovascular risk in ESRD by a global approach including proteomic evaluation
|
Ziad Massy, Amiens, France
|
Saturday, June 23 2007 – 9.00-10.30 |
Clinicopathological conference |
Focal segmental glomerulosclerosis: unitary interpretation of a pluralistic appearance |
Clinician: Alain Meyrier, Paris, France
Pathologist: Ian Roberts, Oxford, United Kingdom |
Saturday, June 23 2007 - 9.00-10.30 |
Evidence based bone disease |
- Vitamin D and analogues and hard end-points: effect on death and cardiovascular outcomes |
Ravi Thadhani, Boston, U.S.A. |
- Guidelines and prescription policies for the control of calcium-phosphate metabolism in ESRD |
John Cunningham, London, United Kingdom |
- Bone disease - bone and beyond |
Hartmut H. Malluche, Lexington,U.S.A. |
Saturday, June 23 2007 – 9.00-10.30 |
Understanding phosphate metabolism: the kidney and beyond
|
- Advances in renal phosphate transport mechanisms: implications for bone disease and nephrolithiasis
|
Gérard Friedlander, Paris, France |
- C/C-5 and Dent’s disease: ten years on |
Olivier Devuyst, Brussels, Belgium |
- Clinical physiology and pathophysiology of phosphatonins |
Rajiv Kumar, Rochester, U.S.A. |
- Phosphate and blood vessels |
Eduardo Slatopolsky, St. Louis, U.S.A. |
Saturday, June 23 2007 – 10.30-12.00 |
New avenues in renal transplantation: tolerance, cloning and xenotransplantation |
- Inducing transplant tolerance: progress and challenges |
Giuseppe Remuzzi, Bergamo, Italy |
- A new strategy for replacing kidneys |
Jeffrey L. Platt, Rochester, U.S.A. |
- Update in xenotransplantation
|
Emanuele Cozzi, Padua, Italy |
Saturday, June 23 2007 – 10.30-12.00
|
- Haemodynamic instability during haemodialysis |
Jeroen Kooman, Maastricht, the Netherlands |
- Vascular access |
Jan Tordoir, Maastricht, the Netherlands |
- Protein and energy malnutrition |
Denis Fouque, Lyon, France |
- Dialysis strategies |
James Tattersall, Leeds, United Kingdom |
Saturday, June 23 2007 – 14.00-15.30
|
Clinical governance and Nephrology
|
- Workforce and staffing of Nephrology Units in Europe |
Alison MacLeod, Aberdeen, United Kingdom |
- Use of Registry data: is demonstration of variation enough to drive up quality?
|
Charles Tomson, Bristol, United Kingdom |
- Governing Nephrology units in the years of scarcity: the challenge of compounding clinical effectiveness, research and development with available resources |
Walter Hörl, Vienna, Austria |
Saturday, June 23 2007 – 14.00-15.30
|
The physical measure of cardiovascular and renal health of the new millennium: pulse wave velocity |
- Is brachial arterial pressure the best way to assess cardiovascular structural damage? An overview and lessons from clinical trials
|
Gérard London, Fleury Merogis, France
|
- Arterial rigidity and the kidney
|
Jacques Blacher, Paris, France |
- Alterations of arterial rigidity in children and adolescents. End stage renal disease and beyond |
Adrian Covic, Iasi, Romania
|
Saturday, June 23 2007 – 14.00-15.30
|
Immuno-pharmacology perspectives in renal transplantation
|
- Blockade of T-cell costimulation: immunoselective maintenance immunosuppression in organ transplantation |
Nader Najafian, Boston, U.S.A
|
- Anti-CD20 based strategies in renal transplantation
|
Helena Genberg, Stockholm, Sweden
|
- Targeting fibrosis in renal transplantation
|
Antonio Dal Canton, Pavia, Italy
|
Saturday, June 23 2007 – 14.00-15.30 |
Salt balance: the vulnerable side of peritoneal dialysis |
- Basic physiology is the salt for PD treatment |
Wim Van Biesen, Ghent, Belgium |
- Residual renal function and the epidemiology of volume overload and hypertension in peritoneal dialysis |
Raymond Krediet, Amsterdam, the Netherlands |
- Fluid balance, nocturnal PD and sleep apnea |
Sidney Tang, Hong Kong, Hong Kong SAR, China |
Saturday, June 23 2007 – 15.45-17.15 |
Ongoing clinical trials |
- A hypothesis generating exercise on cardiovascular risk in ESRD: secondary analyses of the 4D study |
Christoph Wanner, Würzburg, Germany |
- New treatment options for ADPKD (results from ongoing clinical trials) |
Gerd Walz, Freiburg, Germany |
- Membrane permeability outcome: results from the MPO Study |
Francesco Locatelli, Lecco, Italy |
- Impact of nocturnal haemodialysis on LV mass, blood pressure, mineral metabolism, and quality of life - Results from a randomized clinical trial |
Bruce Culleton, Calgary, Canada |
Saturday, June 23 2007 – 15.45-17.45 |
Clinical practice trends and outcomes from international Dialysis studies: DOPPS and Cosmos |
- Trends in following European Best Practice Guidelines and Outcomes |
Bernard Canaud, Montpellier, France |
- Results from the Cosmos Study |
Jorge B. Cannata-Andía, Oviedo, Spain |
- Advantages of facility-level analyses |
Robert A. Wolfe, Ann Arbor, U.S.A. |
- Trends in catheter use in 12 countries and associated outcomes |
Vittorio E. Andreucci, Naples, Italy |
- Trends in cardiac medication use and associated outcomes |
Antonio A. Lopes, Salvador de Bahia, Brazil |
- Panel discussion |
Sunday, June 24 2007 – 9.00-10.30 |
Progress in renal transplantation monitoring |
- Clinical implications of monitoring plasma levels of currently used immuno-suppressive drugs |
José M Morales, Madrid, Spain |
- Gene profiling of renal allografts |
Rainer Oberbauer, Linz, Austria |
- Proteomics and protocol biopsies to detect rejection |
Hermann Haller, Hannover, Germany |
Sunday, June 24 2007 – 11.00-12.30 |
New frontiers in critical care Nephrology |
- Energy and protein intake in critically ill patients with ARF |
Enrico Fiaccadori, Parma, Italy |
- Insulin resistance in the critically ill patient. Prognostic and therapeutic implications |
Talat Alp İkizler, Nashville, U.S.A. |
- Extended daily dialysis for treatment of ARF in the ICU |
Jan Kielstein, Stanford, U.S.A. |
- Gene therapy in the treatment of acute renal failure |
Josep M. Grinyo, Barcelona, Spain |
Sunday, June 24 2007 – 11.00-12.30 |
KDIGO |
- KDIGO - past, present and future of Global Guidelines |
Norbert Lameire, Ghent, Belgium |
- KDIGO Guidelines on Hepatitis C in CKD |
Michel Jadoul, Brussels, Belgium |
- Process of establishing KDIGO Guidelines on bone and mineral disorders in CKD |
Tilman Drueke, Paris, France |
Friday, June 22 2007 – 17.30-18.15 |
Hypertension – CV risk – Preventive Nephrology |
Dimitrios Tsakiris, Thessaloniki, Greece |
Friday, June 22 2007 – 17.30-18.15 |
Dialysis |
Bernard Canaud, Montpellier, France |
Friday, June 22 2007 – 17.30-18.15 |
Basic Science and Transitional Nephrology |
Jürgen Floege, Aachen, Germany |
&nbs |